Ms. Connell is a commercial executive with business development expertiseAppointment takes place as Opthea prepares for Phase 3 wet AMD topline ...
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback